Highly efficient removal of tumor necrosis factor-α(TNF-α)from plasma by hemoperfusion for autoim-mune disease therapy remains a challenge in the clinical field owing to the low adsorption capacity and poor blood co...Highly efficient removal of tumor necrosis factor-α(TNF-α)from plasma by hemoperfusion for autoim-mune disease therapy remains a challenge in the clinical field owing to the low adsorption capacity and poor blood compatibility of adsorbents.In this work,a new class of nanobody(Nb)-coupled antifouling polyvinyl alcohol(PVA)beads was constructed as an immunosorbent for the selective removal of TNF-αfrom plasma.Notably,our immunosorbent exhibited an exceptionally high specific TNF-αadsorption ca-pacity of 416.9 ng/g in human plasma(at a plasma-to-adsorbent ratio of 300).More importantly,the ob-tained adsorbent beads showed outstanding blood compatibility.In addition,during in vivo experiments,the blood circulation device was constructed to remove TNF-αin rat models,proving that the beads had good removal performance(∼85%/60 min).Furthermore,95%of the original capacity was retained after 6-month storage,showed strong stability and prolonged storage of PVA-Nb.Above all,the results indi-cate that the novel PVA-Nb immunosorbent has possible clinical applications for treating autoimmune diseases in the clinic.展开更多
Highly efficient removal of bilirubin from whole blood directly by hemoperfusion for liver failure therapy remains a challenge in the clinical field due to the low adsorption capacity,poor mechanical strength and low ...Highly efficient removal of bilirubin from whole blood directly by hemoperfusion for liver failure therapy remains a challenge in the clinical field due to the low adsorption capacity,poor mechanical strength and low biocompatibility of adsorbents.In this work,a new class of nanocomposite adsorbents was constructed through an inorganic-organic co-crosslinked nanocomposite network between vinyltriethoxysilane(VTES)-functionalized hydroxyapatite nanoparticles(V-Hap)and non-ionic styrene-divinylbenzene(PS-DVB)resins(PS-DVB/V-Hap)using suspension polymerization.Notably,our adsorbent demonstrated substantially improved mechanical performance compared to the pure polymer,with the hardness and modulus increasing by nearly 3 and 2.5 times,respectively.Moreover,due to the development of a mesoporous structure,the prepared PS-DVB/V-Hap3 exhibited an ideal adsorption capacity of 40.27 mg·g^(-1).More importantly,the obtained adsorbent beads showed outstanding blood compatibility and biocompatibility.Furthermore,in vivo extracorporeal hemoperfusion verified the efficacy and biosafety of the adsorbent for directly removing bilirubin from whole blood in pig models,and this material could potentially prevent liver damage and improve clinical outcomes.Taken together,the results suggest that PS-DVB/V-Hap3 beads can be used in commercial adsorption columns to threat hyperbilirubinemia patients through hemoperfusion,thus replacing the existing techniques where plasma separation is initially required.展开更多
基金supported by grants from the National Key R&D Program of China(No.2017YFC1104401)the National Natu-ral Science Foundation of China(No.81771986)+1 种基金the Natural Sci-ence Foundation of Tianjin(No.18YFZCSY00860)the Scientific Research Translational Foundation of Wenzhou Safety(Emergency)Institute of Tianjin University(No.TJUWYY2022004).
文摘Highly efficient removal of tumor necrosis factor-α(TNF-α)from plasma by hemoperfusion for autoim-mune disease therapy remains a challenge in the clinical field owing to the low adsorption capacity and poor blood compatibility of adsorbents.In this work,a new class of nanobody(Nb)-coupled antifouling polyvinyl alcohol(PVA)beads was constructed as an immunosorbent for the selective removal of TNF-αfrom plasma.Notably,our immunosorbent exhibited an exceptionally high specific TNF-αadsorption ca-pacity of 416.9 ng/g in human plasma(at a plasma-to-adsorbent ratio of 300).More importantly,the ob-tained adsorbent beads showed outstanding blood compatibility.In addition,during in vivo experiments,the blood circulation device was constructed to remove TNF-αin rat models,proving that the beads had good removal performance(∼85%/60 min).Furthermore,95%of the original capacity was retained after 6-month storage,showed strong stability and prolonged storage of PVA-Nb.Above all,the results indi-cate that the novel PVA-Nb immunosorbent has possible clinical applications for treating autoimmune diseases in the clinic.
基金The authors are thankful for the financial support from the National Key Research and Development Program of China(2017YFC1104401)the National Natural Science Foundation of China(81771986)the Natural Science Foundation of Tianjin(18YFZCSY00860).
文摘Highly efficient removal of bilirubin from whole blood directly by hemoperfusion for liver failure therapy remains a challenge in the clinical field due to the low adsorption capacity,poor mechanical strength and low biocompatibility of adsorbents.In this work,a new class of nanocomposite adsorbents was constructed through an inorganic-organic co-crosslinked nanocomposite network between vinyltriethoxysilane(VTES)-functionalized hydroxyapatite nanoparticles(V-Hap)and non-ionic styrene-divinylbenzene(PS-DVB)resins(PS-DVB/V-Hap)using suspension polymerization.Notably,our adsorbent demonstrated substantially improved mechanical performance compared to the pure polymer,with the hardness and modulus increasing by nearly 3 and 2.5 times,respectively.Moreover,due to the development of a mesoporous structure,the prepared PS-DVB/V-Hap3 exhibited an ideal adsorption capacity of 40.27 mg·g^(-1).More importantly,the obtained adsorbent beads showed outstanding blood compatibility and biocompatibility.Furthermore,in vivo extracorporeal hemoperfusion verified the efficacy and biosafety of the adsorbent for directly removing bilirubin from whole blood in pig models,and this material could potentially prevent liver damage and improve clinical outcomes.Taken together,the results suggest that PS-DVB/V-Hap3 beads can be used in commercial adsorption columns to threat hyperbilirubinemia patients through hemoperfusion,thus replacing the existing techniques where plasma separation is initially required.